Zymeworks Current Ratio 2016-2022 | ZYME

Zymeworks current ratio from 2016 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Zymeworks Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $0.26B $0.08B 3.29
2022-03-31 $0.32B $0.08B 4.05
2021-12-31 $0.29B $0.07B 4.01
2021-09-30 $0.34B $0.08B 4.47
2021-06-30 $0.39B $0.08B 4.73
2021-03-31 $0.43B $0.07B 6.16
2020-12-31 $0.46B $0.09B 5.31
2020-09-30 $0.49B $0.10B 5.03
2020-06-30 $0.47B $0.07B 6.48
2020-03-31 $0.51B $0.07B 6.92
2019-12-31 $0.31B $0.08B 3.78
2019-09-30 $0.35B $0.05B 6.81
2019-06-30 $0.37B $0.04B 9.07
2019-03-31 $0.19B $0.03B 6.76
2018-12-31 $0.20B $0.03B 6.82
2018-09-30 $0.15B $0.02B 6.42
2018-06-30 $0.17B $0.02B 7.26
2018-03-31 $0.07B $0.02B 4.09
2017-12-31 $0.09B $0.02B 6.30
2017-09-30 $0.05B $0.01B 4.57
2017-06-30 $0.07B $0.01B 5.60
2017-03-31 $0.03B $0.02B 1.57
2016-12-31 $0.05B $0.02B 2.81
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.02B $0.01B 3.64
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.478B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $172.495B 10.52
GSK (GSK) United Kingdom $71.890B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.605B 0.00
Arcus Biosciences (RCUS) United States $2.586B 38.81
Biohaven (BHVN) United States $1.141B 0.00
Emergent Biosolutions (EBS) United States $0.599B 4.71
ADC Therapeutics SA (ADCT) Switzerland $0.278B 0.00
Enzo Biochem (ENZ) United States $0.096B 0.00
SQZ Biotechnologies (SQZ) United States $0.046B 0.00
Gelesis Holdings (GLS) United States $0.035B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00